Weeks 1-4 execution — daily and weekly rhythm

Phase 1 is the reset. You are not chasing weight loss yet. You are downregulating a hyperinsulinemic, GIP-resistant, mitochondrially-sluggish metabolism — and the next twenty-eight days is where the receptor reset happens. Botch the titration here and Phase 2 won't land. Run it clean and the rebuild phase compounds on a substrate that's actually listening. [short pause] Here's what's happening in your tissues during Phase 1. The dual G-L-P 1 slash G-I-P agonist binds INCRETIN RECEPTORS that have been chronically downregulated by years of post-prandial glucose excursions. The first four weeks are pharmacodynamic adaptation, not therapeutic effect. Receptor density on pancreatic beta cells, hypothalamic P-O-M-C neurons, and gastric vagal afferents is recovering. The slow titration exists because that recovery is biphasic — too much agonist load too fast, and the AREA POSTREMA, a chemoreceptor zone with a porous blood-brain barrier, triggers nausea and vomiting cascades that derail the entire protocol. Practitioner consensus is explicit: every case of starvation ketoacidosis and euglycemic D-K-A reported in the literature for this class involved either skipped titration or concurrent ketogenic restriction during the ramp. Don't do either. [short pause] Mitochondrial priming runs underneath. MOTS-c is encoded in mitochondrial D-N-A itself — a signaling peptide produced by the organelles it optimizes. While the G-L-P 1 slash G-I-P agonist is forcing the pancreas to unload, MOTS-c is upregulating AMPK in skeletal muscle, restoring insulin-stimulated glucose uptake at the cellular level. The two compounds work different floors of the same building. Phase 1 starts both engines at low RPM. The injection rhythm itself matters. Weekly dosing of the incretin agonist on a fixed day creates a predictable plasma trough, peak, trough curve, which the area postrema habituates to. Move the day around and you re-trigger the nausea cascade. Lock the day. [short pause] Now to the Phase 1 stack. Tirzepatide at two and a half milligrams across weeks one through four, subcutaneous in the abdomen, once weekly on a fixed day — this is clinical-tier evidence. The two and a half milligram starting dose is mandatory. Do not skip to five milligrams. The substrate is unambiguous: skipped titration drives nearly every G-I and E-K-A adverse-event report. Next, MOTS-c at five milligrams, subcutaneous in the abdomen or thigh, three times per week on Monday, Wednesday, and Friday — expert-tier evidence. This is Protocol A, conservative: a four-week ramp before considering ten milligrams. Total per cycle, sixty milligrams. Then the cofactors. Magnesium glycinate at four hundred milligrams orally with dinner daily — required, because MOTS-c upregulates over three hundred magnesium-dependent enzymatic reactions including ATP synthesis. Deficiency equals a fatigue plateau. A methylated B-complex, one capsule orally each morning, fuels the folate cycle that MOTS-c optimizes. And electrolytes — sodium, potassium, magnesium per label, daily — because G-L-P 1 agonists suppress thirst, and subclinical dehydration accounts for most of the so-called "week two fatigue" reports. [short pause] Daily rhythm. Every morning, seven days a week, three things. First, a fasted CGM read: log the overnight floor. You want stable, not spiking. A pre-meal floor that drifts up week-over-week is the signal that titration is working. Second, weight and waist, consistent time, same scale. Third, subjective scores — hunger one to ten, energy one to ten, G-I one to ten. Three numbers. Takes fifteen seconds. Skip this and you lose the leading indicators. At every meal, protein first. Aim for one point six to two point two grams per kilogram of lean mass daily, spread across three meals. The incretin agonist suppresses appetite globally — without a protein floor you will lose lean mass alongside fat mass. That's iatrogenic sarcopenia, not weight loss. Stop at seventy percent full. The compound is doing satiety work for you. Push past the signal and you trigger the nausea response. And avoid ketogenic carbohydrate restriction during the ramp. The published E-K-A case reports all involved concurrent low-carb intake. Keep complex carbs in the diet at least at maintenance level for Phase 1. [short pause] Weekly rhythm. Monday is a MOTS-c injection day: five milligrams subcutaneous, rotating the site — this week, left abdomen lateral. On reconstitution, if you are using a ten milligram vial with two milliliters of bacteriostatic water, that gives you five milligrams per milliliter, which is fifty units on an insulin syringe per five milligram dose. Wednesday, five milligrams subcutaneous, right abdomen lateral. Friday, five milligrams subcutaneous, left thigh or right abdomen, alternating. Document the site each time. Your Tirzepatide injection day is your choice — but pick one day and lock it. Two and a half milligrams subcutaneous in the abdomen, at least two inches from the navel, and a different site than the MOTS-c injections of the day before or after. Reconstitution and dose math depend on your vial size — verify with the DoseCraft calculator. Practitioner consensus: do this once at the start of Week One and don't change it. Best paired with a low-fat dinner. High-fat meals on injection day amplify nausea via delayed gastric emptying. Sunday is your weekly review, fifteen minutes. Plot the week's CGM trend. Is the pre-meal floor moving down? Is the post-meal ceiling lower? Is time-to-baseline shorter? These are the three leading indicators. Fasting glucose alone won't tell you. Then a compliance honest-audit: did you hit the protein floor? Hydrate? Skip injections? And check your site rotation map: are you favoring one spot? LIPOHYPERTROPHY at a favored site blunts absorption. [short pause] Here's what you should feel, week by week. Week one: mild appetite reduction within twenty-four to forty-eight hours of the Tirzepatide injection. Possible transient nausea on days two through four. Energy unchanged or slightly lower — MOTS-c is priming, not yet performing. Week two: hunger noticeably blunted between meals. Sweet cravings drop hard — this is the GIP arm engaging. Possible ramp fatigue mid-week; magnesium and hydration handle most of it. Week three: fasted glucose begins to drift down, modestly — five to ten milligrams per deciliter if you started elevated. CGM pre-meal floor stabilizes. Sleep often improves. Week four: energy returns and exceeds baseline. This is MOTS-c starting to perform. Weight down two to four pounds typical, though the win you're tracking is the metabolic markers, not the scale. Prepare for the Week Five Tirzepatide titration to five milligrams. [short pause] Now, what's NOT happening yet. You are not in the G-L-P 1 weight-loss phase. The fifteen to twenty percent body weight reductions reported in the Phase 3 trials happen over seventy-two weeks at maintenance doses. Week Four at two and a half milligrams is sub-therapeutic for weight loss by design. The point is receptor reset. HbA1c is not moving. It lags eight to twelve weeks. Don't re-pull it. Fasting insulin and HOMA-I-R are your Week Four markers. Don't chase the dose. If Week Three G-I symptoms are minor, you might be tempted to jump to five milligrams early. Don't. The titration protects you from the very adverse events that derail people. Energy lag in Week Two is not a MOTS-c failure. Mitochondrial biogenesis takes fourteen to twenty-one days to register subjectively. If energy is still suppressed by the end of Week Four, the issue is almost always magnesium, B-vitamins, or sleep — not the compound. And finally: a few skipped injection days don't ruin the protocol — but moving the Tirzepatide day around does. Receptor habituation depends on plasma rhythm. The chosen day is sacred. [short pause] The practitioner corpus describes this rhythm with unusual consistency. Run it as written for twenty-eight days. Then we titrate.